zintick

Beta Bionics BBNX

Beta Bionics, Inc. · Nasdaq · Surgical & Medical Instruments & Apparatus

$17.85-16.55%close on Oct. 28, 2026 · volume 2.5M · Yahoo Finance

Price, last 47 sessions

$18.00$20.00$22.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $22.81 · low $16.35 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 26, 2026Mark Hopman
Chief Commercial Officer
Sold
10b5-1 plan
821$20.00$16,420
Oct. 14, 2026Mark Hopman
Chief Commercial Officer
Sold775$17.35$13,446
Oct. 1, 2026Mark Hopman
Chief Commercial Officer
Sold370$18.96$7,015
Sept. 22, 2026Christy Jones
director
Sold
10b5-1 plan
6,430$23.00$147,890
Sept. 16, 2026Mark Hopman
Chief Commercial Officer
Sold
10b5-1 plan
30,779$20.13$619,640
Sept. 16, 2026Mike Mensinger
Chief Product Officer
Sold
10b5-1 plan
2,650$22.00$58,300
Sept. 14, 2026Mark Hopman
Chief Commercial Officer
Sold
10b5-1 plan
775$15.52$12,028
Sept. 9, 2026Mark Hopman
Chief Commercial Officer
Sold
10b5-1 plan
amended
35,994$18.46$664,550
Sept. 3, 2026Sean Saint
President & CEO, director
Sold
10b5-1 plan
5,641$20.08$113,259
Sept. 2, 2026Mark Hopman
Chief Commercial Officer
Sold5,327$19.11$101,815
Sept. 2, 2026Steven Jon Russell
Chief Medical Officer
Sold4,221$19.11$80,676
Sept. 2, 2026Mike Mensinger
Chief Product Officer
Sold4,375$19.11$83,620

Latest 12 of 14. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 26 →
  • 4Oct. 28, 2026, 4:03 p.m. ETView on SEC.gov
  • 10-QOct. 27, 2026, 4:20 p.m. ETView on SEC.gov
  • 8-KOct. 27, 2026, 4:04 p.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedBeta Bionics Q3 2026 Net Sales Rise 30% to $35.5 Million, Beating Consensus; Full-Year Revenue Guidance Low End Raised to $124 Million

  • 4Oct. 16, 2026, 4:10 p.m. ETView on SEC.gov
  • SCHEDULE 13GOct. 7, 2026, 2:56 p.m. ETView on SEC.gov
  • 4Oct. 5, 2026, 5:11 p.m. ETView on SEC.gov
  • 4Sept. 23, 2026, 5:40 p.m. ETView on SEC.gov
  • 4/ASept. 18, 2026, 7:51 p.m. ETView on SEC.gov